Ovarian Cancer and Us - best viewed in FIREFOX

Search: this blog, links from posts and the web.....

Loading...

Wednesday, November 14, 2012

press release: PRIMA BIOMED RELEASES INTERIM IMMUNE MONITORING DATA FROM CVAC CLINICAL TRIAL (CVac/ovarian)





About CAN-003

"CAN-003 is an open label, randomized, multinational, controlled phase 2 study. Sixty-three ovarian cancer patients in first or second remission have been enrolled. The first seven patients were not randomized and all received CVac. Subsequently, 29 patients were randomized to the CVac
group compared to 27 patients in the observation standard of care group."


ASX/Media Release 14 November 2012


PRIMA BIOMED RELEASES INTERIM IMMUNE MONITORING DATA FROM CVAC CLINICAL TRIAL

• Interim immune monitoring data demonstrate positive effects of CVacTM
• Conference call to present the data scheduled for November 15th

0 comments :

Post a Comment

Your opinions and views?